United States - English - NLM (National Library of Medicine)

sothys paris - avobenzone 3% homosalate 10% octisalate 5% octocrylene 8%, sunscreen - - helps prevent sunburn - if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

sothys paris - octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox) - - helps prevent sunburn - if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - latanoprost (unii: 6z5b6hvf6o) (latanoprost - unii:6z5b6hvf6o) - latanoprost sterile ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. teratogenic effects: pregnancy category c. reproduction studies have been performed in rats and rabbits. in rabbits, an incidence of 4 of 16 dams had no viable fetuses at a dose that was approximately 80 times the maximum human dose, and the highest nonembryocidal dose in rabbits was approximately 15 times the maximum human dose. there are no adequate and well-controlled studies in pregnant women. latanoprost should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. it is not known whether this drug or its metabolites are excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when latanoprost is administered to a nursing woman. safety and effectiveness in

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. furosemide tablets are particularly useful when an agent with greater diuretic potential is desired. oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.

United States - English - NLM (National Library of Medicine)

sandoz inc - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24) - cetirizine hydrochloride 5 mg - antihistamine temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:

United States - English - NLM (National Library of Medicine)

a-s medication solutions - norelgestromin (unii: r0tay3x631) (norelgestromin - unii:r0tay3x631), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norelgestromin 150 ug in 1 d - xulane is indicated for the prevention of pregnancy in women with a body mass index (bmi) < 30  kg/m2 for whom a combined hormonal contraceptive is appropriate. limitations of use: xulane may be less effective in preventing pregnancy in women who weigh 198 lbs. (90 kg) or more. xulane is contraindicated for use in women with bmi ≥ 30 kg/m2  [see contraindications (4), warnings and precautions (5.1) and clinical studies (14)] . xulane is contraindicated in females who are known to have or develop the following conditions: there is little or no increased risk of birth defects in women who inadvertently use hormonal contraceptives during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose hormonal contraceptives prior to conception or during early pregnancy. the administration of hormonal contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. hormonal contraceptives should not be used during pregnancy to treat threatened or habitual abortion. the effects of xulane in nursing mothers have not been evaluated and are unknown. when possible, advise the nursing mother to use other forms of contraception until she has completely weaned her child. estrogen-containing chcs can reduce milk production in breastfeeding mothers. this is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. small amounts of contraceptive steroids and/or metabolites are present in breast milk. safety and efficacy of norelgestromin and ethinyl estradiol transdermal system have been established in women of reproductive age. efficacy is expected to be the same for post-pubertal adolescents under the age of 18 and for users 18 years and older. use of this product before menarche is not indicated. xulane has not been studied in postmenopausal women and is not indicated in this population. no studies with xulane have been conducted in women with hepatic impairment. however, steroid hormones may be poorly metabolized in patients with impaired liver function. acute or chronic disturbances of liver function may necessitate the discontinuation of combined hormonal contraceptive use until markers of liver function return to normal and combined hormonal contraceptive causation has been excluded. [see contraindications (4) and warnings and precautions (5.3).] no studies with xulane have been conducted in women with renal impairment. xulane is contraindicated in women with a bmi ≥ 30 kg/m2 because of the potential increased risk of vte [see contraindications (4) and warnings and precautions (5.1)]. xulane may be less effective in preventing pregnancy in women who weigh 198 lbs. or more [see clinical studies (14)].

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - dexmethylphenidate hydrochloride (unii: 1678ok0e08) (dexmethylphenidate - unii:m32rh9mfgp) - dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients aged 6 years and older. the effectiveness of dexmethylphenidate hydrochloride extended-release in the treatment of adhd in patients aged 6 years and older was established in 2 placebo-controlled studies in patients meeting dsm-iv criteria for adhd [see clinical studies (14) ]. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. for the hyperactive-impulsive type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can’t wait turn; intrusive. the combined types requires both inattentive and hyperactive-impulsive criteria to be met. special diagnostic considerations specific etiology of this syndrome is unknown, and there is no single diagnostic test. adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. learning may or may not be impaired. the diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of dsm-iv characteristics. need for comprehensive treatment program dexmethylphenidate hydrochloride extended-release capsules are indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational, social) for patients with this syndrome. drug treatment may not be indicated for all children with this syndrome. stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms. long-term use the effectiveness of dexmethylphenidate hydrochloride extended-release for long-term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. therefore, the physician who elects to use dexmethylphenidate hydrochloride extended-release for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient [see dosage and administration (2.3 )]. dexmethylphenidate hydrochloride extended-release is contraindicated in patients with marked anxiety, tension, and agitation, since the drug may aggravate these symptoms. dexmethylphenidate hydrochloride extended-release is contraindicated in patients known to be hypersensitive to methylphenidate, or other components of the product. hypersensitivity reactions, including angioedema and anaphylactic reactions, have been observed in patients treated with methylphenidate [see adverse reactions (6.5, 6.6 )]. dexmethylphenidate hydrochloride extended-release is contraindicated in patients with glaucoma. dexmethylphenidate hydrochloride extended-release is contraindicated in patients with motor tics or with a family history or diagnosis of tourette’s syndrome [see adverse reactions (6.1) ]. dexmethylphenidate hydrochloride extended-release is contraindicated during treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor (hypertensive crises may result). pregnancy category c: there are no adequate and well controlled studies of dexmethylphenidate hydrochloride in pregnant women. dexmethylphenidate did not cause major malformations in rats or rabbits; however, it did cause delayed skeletal ossification and decreased postweaning weight gain in rats. dexmethylphenidate hydrochloride extended-release should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in studies conducted in rats and rabbits, dexmethylphenidate was administered orally at doses of up to 20 and 100 mg/kg/day, respectively, during the period of organogenesis. no evidence of teratogenic activity was found in either the rat or rabbit study; however, delayed fetal skeletal ossification was observed at the highest dose level in rats. when dexmethylphenidate was administered to rats throughout pregnancy and lactation at doses of up to 20 mg/kg/day, postweaning body weight gain was decreased in male offspring at the highest dose, but no other effects on postnatal development were observed. at the highest doses tested, plasma levels (aucs) of dexmethylphenidate in pregnant rats and rabbits were approximately 5 and 1 times, respectively, those in adults dosed with 20 mg/day. racemic methylphenidate has been shown to have teratogenic effects in rabbits when given in doses of 200 mg/kg/day throughout organogenesis. dexmethylphenidate hydrochloride extended-release has not been studied in labor and delivery. it is not known whether dexmethylphenidate is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised if dexmethylphenidate hydrochloride extended-release is administered to a nursing woman. information from 4 published case reports on the use of racemic methylphenidate during breastfeeding suggest that at maternal doses of 35 to 80 mg/day, milk concentrations of methylphenidate range from undetectable to 15.4 ng/ml. based on these limited data, the calculated infant daily dose for an exclusively breastfed infant would be about 0.4 to 2.9 µg/kg/day or about 0.2 to 0.7% of the maternal weight adjusted dose. the safety and efficacy of dexmethylphenidate hydrochloride extended-release in children under 6 years old have not been established. long-term effects of dexmethylphenidate hydrochloride in children have not been well established [see warnings and precautions (5.13) ]. in a study conducted in young rats, racemic methylphenidate was administered orally at doses of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (postnatal day 7) and continuing through sexual maturity (postnatal week 10). when these animals were tested as adults (postnatal weeks 13-14), decreased spontaneous locomotor activity was observed in males and females previously treated with 50 mg/kg/day (approximately 6 times the maximum recommended human dose [mrhd] of racemic methylphenidate on a mg/m2 basis) or greater, and a deficit in the acquisition of a specific learning task was seen in females exposed to the highest dose (12 times the racemic mrhd on a mg/m2 basis). the no effect level for juvenile neurobehavioral development in rats was 5 mg/kg/day (half the racemic mrhd on a mg/m2 basis). the clinical significance of the long-term behavioral effects observed in rats is unknown. dexmethylphenidate hydrochloride extended-release has not been studied in the geriatric population. dexmethylphenidate hydrochloride extended-release, like other methylphenidate products, is classified as a schedule ii controlled substance by federal regulation. see the complete boxed warning for drug abuse and dependence information at the beginning of full prescribing information .

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - chlorthalidone (unii: q0mqd1073q) (chlorthalidone - unii:q0mqd1073q) - diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. chlorthalidone is indicated in pregnancy when edema is due to

United States - English - NLM (National Library of Medicine)

conopco, inc. d/b/a unilever - aluminum chlorohydrate (unii: hpn8mzw13m) (aluminum chlorohydrate - unii:hpn8mzw13m) - antiperspirant reduces underarm wetness

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: - active duodenal ulcer (du). - active gastric ulcer (gu). - symptomatic nonerosive gastroesophageal reflux disease (gerd). - erosive esophagitis due to gerd, diagnosed by biopsy. famotidine tablets are indicated in adults for the: - treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome, multiple endocrine neoplasias). - reduction of the risk of duodenal ulcer recurrence. famotidine is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2 ) receptor antagonists. risk summary available data with h2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administration of fa